Other · developed by RANI Therapeutics
PG-102 is a drug studied for the treatment of obesity.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06891287 | Phase 1 | Obesity | Recruiting | RANI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Obesity
Updated Oct 25, 2026. Something wrong or missing? Report it on the RANI page.
See RANI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RANI catalysts and pipeline →